Emerald Bioscience’s NB1111 Demonstrates Superiority in Lowering Intraocular Pressure Compared to Global Standard of Care Glaucoma Treatment in Preclinical Model
15. Oktober 2019 08:35 ET
|
Emerald Bioscience, Inc.
LONG BEACH, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global...